Upward Sales, but Procter & Gamble Shares No Bargain

We believe investors should await a more favorable entry point before buying shares of this wide-moat firm.

Securities In This Article
Procter & Gamble Co
(PG)

Procter & Gamble’s PG run (now at seven consecutive quarters) of mid- to high-single-digit organic top-line gains continued unfettered in its second fiscal quarter. We surmise this performance was more salient when considering the solid comparisons it lapped (4% growth in the prior-year period) and the extent to which this growth has proven broad-based (with four of its five segments boasting underlying sales increases in the 4%-8% range) and balanced (straddling increased volumes and higher prices, up 3% and 2%, respectively). As opposed to evidencing industry tailwinds, we attribute this to intentional actions taken by the firm over a multi-year horizon (including rationalizing its portfolio mix, driving efficiency savings, and funneling additional resources behind its core brand offerings) to reignite its top line and support its brand intangible asset (which when combined with its cost edge underlays its wide moat). However, we’ve been impressed these gains haven’t encumbered profits. As evidence, adjusted gross margins popped 200 basis points in the quarter to 49.6% (reflecting a 120-basis-point benefit from productivity initiatives), while adjusted operating margins ticked up 190 basis points to 22.8% despite a 150-basis-point increase in marketing.

While management edged up its full-year organic sales (to 4%-5% from 3%-5%) and adjusted EPS guidance (to 8%-11% from 5%-10%), we don’t anticipate altering our near-term forecast that continues to align with P&G’s updated marks (at 4.3% and 8.5%, respectively). Further, we’re holding the line on our $106 fair value estimate and long-term expectations (3%-4% annual sales growth and more than 24% operating margins by fiscal 2029, up from an average of 21.6% over the past three years). But trading at nearly a 20% premium to our intrinsic value, we don’t think the shares reflect looming competitive and macro headwinds and tougher second-half comparisons; we believe investors should await a more favorable entry point.

Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.

More in Stocks

About the Author

Erin Lash, CFA

Sector Director
More from Author

Erin Lash, CFA, is a sector director, AM Consumer, for Morningstar*. In addition to leading the sector team, she covers packaged food and household and personal care companies. Beyond managing a team of nine analysts and associates covering an array of consumer firms, Lash also conducts fundamental analysis of 13 multi-billion-dollar market capitalization firms in the packaged food and household and personal care space.

Before joining Morningstar in 2006, Lash spent four years as an investment analyst covering retail, transportation, and technology firms for State Farm Insurance. In this capacity, Lash analyzed financial statements, business strategy, and fundamentals of owned companies and potential investments, presenting her recommendations based on this analysis to State Farm portfolio managers for ownership consideration.

Lash holds a bachelor’s degree in finance from Bradley University’s Foster College of Business. She also holds a master’s degree in business administration, with concentrations in accounting and finance, from the University of Chicago Booth School of Business. Lash has completed the Chartered Financial Analyst® designation. She ranked second in the food and tobacco industry in The Wall Street Journal’s annual “Best on the Street” analysts survey in 2013, the last year the survey was conducted.

* Morningstar Research Services LLC (“Morningstar”) is a wholly owned subsidiary of Morningstar, Inc

Sponsor Center